Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out. 

In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.